5 results on '"Kitchener, Henry"'
Search Results
2. Age‐specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot.
- Author
-
Rebolj, Matejka, Mathews, Christopher S., Pesola, Francesca, Cuschieri, Kate, Denton, Karin, Kitchener, Henry, Appleyard, Tracey‐Louise, Cruickshank, Margaret, Ellis, Kay, Evans, Chris, Frew, Viki, Giles, Thomas, Gray, Alastair, Holbrook, Miles, Hunt, Katherine, Levine, Tanya, McBride, Emily, Mesher, David, Palmer, Timothy, and Parker, Janet
- Subjects
MEDICAL screening ,CERVICAL intraepithelial neoplasia ,VACCINATION status ,VACCINATION ,SCIENTIFIC observation - Abstract
Objective: To report detailed age‐specific outcomes from the first round of an English pilot studying the implementation of high‐risk human papillomavirus (HR‐HPV) testing in primary cervical screening. Design: Observational study with screening in 2013–2016, followed by two early recalls and/or colposcopy until the end of 2019. Setting: Six NHS laboratory sites. Population: A total of 1 341 584 women undergoing screening with HR‐HPV testing or liquid‐based cytology (LBC). Methods: Early recall tests and colposcopies were recommended, depending on the nature of the screening‐detected abnormality. Main outcome measures: We reported standard screening process indicators, e.g. proportions with an abnormality, including high‐grade cervical intraepithelial neoplasia (CIN2+) or cancer, and the positive predictive value (PPV) of colposcopy for CIN2+, by screening test and age group. Results: Among unvaccinated women screened with HR‐HPV testing at age 24–29 years, 26.9% had a positive test and 10.4% were directly referred to colposcopy following cytology triage, with a PPV for CIN2+ of 47%. At 50–64 years of age, these proportions were much lower: 5.3%, 1.2% and 27%, respectively. The proportions of women testing positive for HR‐HPV without cytological abnormalities, whose early recall HR‐HPV tests returned negative results, were similar across the age spans: 54% at 24–29 years and 55% at 50–64 years. Two‐thirds of infections at any age were linked to non‐16/18 genotypes. Among women with CIN2, CIN3 or cervical cancer, however, the proportion of non‐16/18 infections increased with age. As expected, the detection of abnormalities was lower following screening with LBC. Conclusions: These data provide a reliable reference for future epidemiological studies, including those concerning the effectiveness of HPV vaccination. Data from the English pilot study provide a comprehensive overview of abnormalities detected through HPV screening. Data from the English pilot study provide a comprehensive overview of abnormalities detected through HPV screening. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia
- Author
-
Lehtinen, Matti, Paavonen, Jorma, Wheeler, Cosette M, Jaisamrarn, Unnop, Garland, Suzanne M, Castellsagué, Xavier, Skinner, S Rachel, Apter, Dan, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Kitchener, Henry, Teixeira, Julio C, Hedrick, James, Limson, Genara, Szarewski, Anne, Romanowski, Barbara, Aoki, Fred Y, Schwarz, Tino F, Poppe, Willy A J, De Carvalho, Newton S, Germar, Maria Julieta V, Peters, Klaus, Mindel, Adrian, De Sutter, Philippe, Bosch, F Xavier, David, Marie-Pierre, Descamps, Dominique, Struyf, Frank, Dubin, Gary, HPV PATRICIA Study Group, and UZB Other
- Subjects
Time Factors ,Hepatitis A vaccine ,Uterine Cervical Neoplasms ,Aluminum Hydroxide ,0302 clinical medicine ,030212 general & internal medicine ,lipid A ,Cervical cancer ,education.field_of_study ,Human papillomavirus 16 ,Human papillomavirus 18 ,Research Support, Non-U.S. Gov't ,HPV infection ,Age Factors ,female genital diseases and pregnancy complications ,3. Good health ,Vaccination ,Europe ,Multicenter Study ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Randomized Controlled Trial ,young adult ,Female ,Adult ,medicine.medical_specialty ,Asia ,Adolescent ,Population ,Cervical intraepithelial neoplasia ,03 medical and health sciences ,Adjuvants, Immunologic ,Double-Blind Method ,Internal medicine ,medicine ,Journal Article ,Humans ,Papillomavirus Vaccines ,Cervical Intraepithelial Neoplasia ,education ,Gynecology ,adenocarcinoma ,business.industry ,Papillomavirus Infections ,Australia ,South America ,medicine.disease ,Vaccine efficacy ,Uterine Cervical Dysplasia ,DNA, Viral ,North America ,Cervarix ,Neoplasm Grading ,business - Abstract
Summary Background Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy against CIN3+, the immediate precursor to invasive cervical cancer, is more difficult to measure because of its lower incidence, but provides the most stringent evidence of potential cancer prevention. We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young Adults). Methods Healthy women aged 15–25 years with no more than six lifetime sexual partners were included in PATRICIA, irrespective of their baseline HPV DNA status, HPV-16 or HPV-18 serostatus, or cytology. Women were randomly assigned (1:1) to receive an HPV-16/18 AS04-adjuvanted vaccine or a control hepatitis A vaccine via an internet-based central randomisation system using a minimisation algorithm to account for age ranges and study sites. The patients and study investigators were masked to allocated vaccine. The primary endpoint of PATRICIA has been reported previously. In the present end-of-study analysis, we focus on CIN3+ and AIS in the populations of most clinical interest, the total vaccinated cohort (TVC) and the TVC-naive. The TVC comprised all women who received at least one vaccine dose, approximating catch-up populations and including sexually active women (vaccine n=9319; control=9325). The TVC-naive comprised women with no evidence of oncogenic HPV infection at baseline, approximating early adolescent HPV exposure (vaccine n=5824; control=5820). This study is registered with ClinicalTrials.gov, number NCT00122681. Findings Vaccine efficacy against CIN3+ associated with HPV-16/18 was 100% (95% CI 85·5–100) in the TVC-naive and 45·7% (22·9–62·2) in the TVC. Vaccine efficacy against all CIN3+ (irrespective of HPV type in the lesion and including lesions with no HPV DNA detected) was 93·2% (78·9–98·7) in the TVC-naive and 45·6% (28·8–58·7) in the TVC. In the TVC-naive, vaccine efficacy against all CIN3+ was higher than 90% in all age groups. In the TVC, vaccine efficacy against all CIN3+ and CIN3+ associated with HPV-16/18 was highest in the 15–17 year age group and progressively decreased in the 18–20 year and 21–25 year age groups. Vaccine efficacy against all AIS was 100% (31·0–100) and 76·9% (16·0–95·8) in the TVC-naive and TVC, respectively. Serious adverse events occurred in 835 (9·0%) and 829 (8·9%) women in the vaccine and control groups, respectively; only ten events (0·1%) and five events (0·1%), respectively, were considered to be related to vaccination. Interpretation PATRICIA end-of-study results show excellent vaccine efficacy against CIN3+ and AIS irrespective of HPV DNA in the lesion. Population-based vaccination that incorporates the HPV-16/18 vaccine and high coverage of early adolescents might have the potential to substantially reduce the incidence of cervical cancer. Funding GlaxoSmithKline Biologicals.
- Published
- 2012
4. Cervical cancer: A global health crisis.
- Author
-
Small, William, Bacon, Monica A., Bajaj, Amishi, Chuang, Linus T., Fisher, Brandon J., Harkenrider, Matthew M., Jhingran, Anuja, Kitchener, Henry C., Mileshkin, Linda R., Viswanathan, Akila N., and Gaffney, David K.
- Subjects
CERVICAL cancer ,PAPILLOMAVIRUS diseases ,EARLY detection of cancer ,CANCER chemotherapy ,VACCINATION - Abstract
Cervical cancer is the fourth most common malignancy diagnosed in women worldwide. Nearly all cases of cervical cancer result from infection with the human papillomavirus, and the prevention of cervical cancer includes screening and vaccination. Primary treatment options for patients with cervical cancer may include surgery or a concurrent chemoradiotherapy regimen consisting of cisplatin-based chemotherapy with external beam radiotherapy and brachytherapy. Cervical cancer causes more than one quarter of a million deaths per year as a result of grossly deficient treatments in many developing countries. This warrants a concerted global effort to counter the shocking loss of life and suffering that largely goes unreported. This article provides a review of the biology, prevention, and treatment of cervical cancer, and discusses the global cervical cancer crisis and efforts to improve the prevention and treatment of the disease in underdeveloped countries. Cancer 2017;123:2404-12. © 2017 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Informing adolescents about human papillomavirus vaccination: What will parents allow?
- Author
-
Vallely, Lorraine A., Roberts, Stephen A., Kitchener, Henry C., and Brabin, Loretta
- Subjects
- *
PAPILLOMAVIRUSES , *VACCINATION , *CERVICAL cancer , *IMMUNIZATION of children - Abstract
Summary: With the introduction of human papillomavirus (HPV) vaccination an evidence base on effective adolescent educational interventions is urgently required. We undertook formative research to develop and evaluate a film on HPV and cervical cancer prevention for school children who will be offered HPV vaccination in the UK. The main outcome measures were the number of children allowed by parents to view the film and children''s knowledge. Our results indicated that the film''s four key messages were acceptable to parents and largely understood by adolescents but these messages will need reinforcing if the full potential of a prophylactic vaccine is to be realised. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.